Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$6.92 +4.0%	$6.15	$3.56 ▼ $12.92	$389.34M	0.48	359,203 shs	152,698 shs
FULC Fulcrum Therapeutics	$6.81 +4.1%	$7.16	$2.32 ▼ $10.13	$368.62M	2.47	588,650 shs	157,175 shs
PRTA Prothena	$7.94 +5.4%	$6.31	$4.32 ▼ $22.83	$427.09M	-0.03	1.06 million shs	890,349 shs
SCLX Scilex	$21.12 +19.5%	$8.61	$3.60 ▼ $49.00	$147.13M	1.32	116,789 shs	309,051 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	-0.45%	-5.27%	+4.40%	+67.51%	-31.86%
FULC Fulcrum Therapeutics	+3.15%	-4.94%	-16.48%	+16.16%	-27.41%
PRTA Prothena	-1.69%	+7.25%	+17.81%	+9.43%	-62.52%
SCLX Scilex	+11.69%	+26.30%	+173.53%	+295.30%	-61.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	2.1847 of 5 stars	3.6	2.0	2.6	1.7	0.0
FULC Fulcrum Therapeutics	1.9531 of 5 stars	3.3	3.0	1.8	1.7	0.0
PRTA Prothena	2.9622 of 5 stars	4.2	2.0	2.3	1.7	0.6
SCLX Scilex	2.6784 of 5 stars	3.3	3.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.25	Buy	$29.00	323.67% Upside
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	11.26% Upside
PRTA Prothena	2.33	Hold	$30.25	277.89% Upside
SCLX Scilex	2.50	Moderate Buy	$455.00	2,097.01% Upside

Current Analyst Ratings Breakdown

Latest SCLX, ATXS, FULC, and PRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ATXS Astria Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	ATXS Astria Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $26.00
8/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/5/2025	PRTA Prothena	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$18.00 ➝ $10.00
8/5/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/5/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.97 per share	N/A
FULC Fulcrum Therapeutics	$80M	4.60	N/A	N/A	$3.96 per share	1.72
PRTA Prothena	$135.16M	3.19	N/A	N/A	$6.03 per share	1.33
SCLX Scilex	$56.59M	2.54	N/A	N/A	($27.68) per share	-0.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$1.87	N/A	N/A	N/A	N/A	-47.18%	-31.26%	N/A
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	N/A
PRTA Prothena	-$122.31M	-$5.64	N/A	N/A	N/A	-2,929.30%	-62.17%	-54.43%	N/A
SCLX Scilex	-$72.81M	-$29.02	N/A	N/A	N/A	-146.93%	N/A	-82.65%	N/A

Latest SCLX, ATXS, FULC, and PRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATXS Astria Therapeutics	-$0.61	-$0.57	+$0.04	-$0.57	N/A	N/A
8/4/2025	Q2 2025	PRTA Prothena	-$1.11	-$1.86	-$0.75	-$2.34	$5.36 million	$4.42 million
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
5/13/2025	Q1 2025	ATXS Astria Therapeutics	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	17.39	17.39
FULC Fulcrum Therapeutics	N/A	24.42	24.42
PRTA Prothena	N/A	5.68	5.68
SCLX Scilex	N/A	0.10	0.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
FULC Fulcrum Therapeutics	89.83%
PRTA Prothena	97.08%
SCLX Scilex	69.67%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
FULC Fulcrum Therapeutics	7.00%
PRTA Prothena	9.20%
SCLX Scilex	7.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.43 million	53.89 million	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable
SCLX Scilex	80	6.95 million	6.40 million	Optionable

SCLX, ATXS, FULC, and PRTA Headlines

Recent News About These Companies

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

August 13 at 6:00 AM | globenewswire.com

Scilex (SCLX) to Release Quarterly Earnings on Tuesday

August 11 at 2:12 AM | americanbankingnews.com

Scilex (SCLX) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Scilex (NASDAQ:SCLX) Stock Price Up 3.7% - Time to Buy?

August 2, 2025 | marketbeat.com

Scilex Holding Co. (SCLX) Stock Price Today - WSJ

July 24, 2025 | wsj.com

SCLX Scilex Holding Company - Seeking Alpha

July 1, 2025 | seekingalpha.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...

June 25, 2025 | theglobeandmail.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

June 23, 2025 | globenewswire.com

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

June 5, 2025 | globenewswire.com

Scilex Holding Stock Price History

June 1, 2025 | investing.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025 | globenewswire.com

Scilex adjusts director compensation post-stock split

May 13, 2025 | investing.com

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025 | globenewswire.com

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

April 30, 2025 | globenewswire.com

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

April 22, 2025 | globenewswire.com

Scilex Gets Orphan Drug Designation for Its Version of Colchicine

April 17, 2025 | marketwatch.com

Scilex treatment of pericarditis granted FDA orphan designation

April 17, 2025 | markets.businessinsider.com

Scilex confirms FDA awards orphan drug designation for colchicine

April 17, 2025 | markets.businessinsider.com

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

April 16, 2025 | globenewswire.com

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

April 15, 2025 | globenewswire.com

Scilex announces 1-for-35 reverse stock split

April 12, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX, ATXS, FULC, and PRTA Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$6.92 +0.27 (+3.98%)

As of 02:17 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Fulcrum Therapeutics NASDAQ:FULC

$6.80 +0.27 (+4.05%)

As of 02:16 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Prothena NASDAQ:PRTA

$7.94 +0.40 (+5.36%)

As of 02:16 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Scilex NASDAQ:SCLX

$21.12 +3.45 (+19.52%)

As of 02:17 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time